Trials / Completed
CompletedNCT01976299
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
AVERT™ Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 578 (actual)
- Sponsor
- Osprey Medical, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
Detailed description
The purpose of this trial is to assess the AVERT System device, which is designed to limit the volume of CM (Contrast Media) utilized, during a staged therapeutic coronary PCI (Percutaneous Coronary Intervention) or a coronary diagnostic procedure that is anticipated to become a PCI (i.e. ad hoc PCI) for the reduction of CIN (Contrast Induced Nephropathy).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | AVERT |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2015-07-01
- Completion
- 2015-09-01
- First posted
- 2013-11-05
- Last updated
- 2017-02-28
- Results posted
- 2017-01-02
Locations
39 sites across 3 countries: United States, Australia, New Zealand
Source: ClinicalTrials.gov record NCT01976299. Inclusion in this directory is not an endorsement.